Ovid Therapeutics Inc. (NASDAQ:OVID)’s quarterly earnings will be published on April, 4., as reported by Faxor. Analysts forecast $-0.55 EPS, which is $0.10 down or 22.22 % from 2018’s $-0.45 EPS. 3.77 % negative EPS growth is what analysts predict. $-0.53 EPS was published for previous quarter. OVID touched $1.94 during the last trading session after $0.05 change.Currently Ovid Therapeutics Inc. is downtrending after 70.14% change in last March 10, 2018. OVID has also 130,016 shares volume. OVID underperformed by 74.51% the S&P500.

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.The firm is valued at $72.08 million. The firm is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome.Last it reported negative earnings. It is also developing OV935, a drug candidate that is in Phase I trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the hospital setting.

For more Ovid Therapeutics Inc. (NASDAQ:OVID) news posted recently go to: Globenewswire.com, Nasdaq.com, Nasdaq.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Ovid Therapeutics Outlines 2019 Clinical and Business Priorities – GlobeNewswire” posted on January 04, 2019, “Wednesday Sector Laggards: Drugs, Defense Stocks – Nasdaq” on February 20, 2019, “Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies – Nasdaq” with a publish date: December 17, 2018, “Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering – Benzinga” and the last “Mid-Day Market Update: LeMaitre Vascular Surges Following Strong Q4 Results; Sienna Biopharmaceuticals Shares Slide – Nasdaq” with publication date: February 20, 2019.